Phase 4 Peripheral Arterial Disease Trial, Recruiting NCT05854641 Sponsor: Cell Biopeutics Resources Sdn Bhd Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Phase 4 Peripheral Arterial Disease Trial, Recruiting

NCT05854641
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 65 years old
  • People who have been diagnosed with a condition called atherosclerotic peripheral arterial disease (a narrowing or blockage of the arteries in the limbs due to fatty deposits)
  • People for whom surgery or a procedure to restore blood flow to the affected area is not an option, or where such treatment has already been tried and has not worked
  • People who have at least one wound or ulcer on the affected area that measures between 0.5 and 10 square centimetres in size
  • People whose blood flow measurements in the lower limbs fall below a certain level, as measured by specific tests (confirm with trial site for exact measurement details)
  • People who are willing and able to give informed consent and agree to follow all study procedures and attend follow-up appointments

Who may not be able to join:

  • People who have been diagnosed with a specific blood vessel disease called Buerger's disease, as identified by a particular set of medical criteria
  • People who are still considered suitable candidates for surgery or a procedure to restore blood flow
  • People who have taken part in another stem cell study or received stem cell therapy within the past 3 months
  • People who the trial doctors consider unsuitable to participate for any other reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Hanafiah Harunarashid, MS, National University of Malaysia

Phone: +60176073103

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Cell Biopeutics Resources Sdn Bhd
Registry
ClinicalTrials.gov
Start date
1 January 2024
Est. completion
1 October 2027

Where this trial is recruiting

🇲🇾 Malaysia

Primary endpoints

Change in ischemic rest pain; Change in size of the ulcer; Change in ankle brachial pressure index (ABPI); Change in total walking distance; Change in major amputation-free survival; Change in angiogenesis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov